MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
HIV/AIDS drug development and treatment
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,576 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,576 works in the cohort · of 4,299,418page 3 of 32

Labels cover 3 of 1,576 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,576 of 1,576 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study
Catherine Orrell, Debbie Hagins, Elena Belonosova, Norma Porteiro, Sharon Walmsley, Vicenç Falcó +93 more
2017· article· en· The Lancet HIV· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
118
citations
affunlabeled
Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected Patients
Marianne Savès, François Raffi, Philippe Clevenbergh, B. Marchou, A. Waldner-Combernoux, Philippe Morlat +4 more
2000· article· en· Antimicrobial Agents and Chemotherapy· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
115
citations
affno abstractunlabeled
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial
Moti Ramgopal, Antonella Castagna, Charles Cazanave, Vicens Díaz-Brito, Robin Dretler, Shinichi Oka +19 more
2023· article· en· The Lancet HIV· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
115
citations
affno abstractunlabeled
Enfuvirtide
Jason A. LaBonte, John Lebbos, Peter Kirkpatrick
2003· review· en· Nature Reviews Drug Discovery· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrity+insufficient_payloadconsensus · metaepi_narrow
98
citations
← previousnext →

How this was built: Screen · Findings · About